Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
The Oakmark Select Fund underperformed the S&P 500 in Q2 2025 but leveraged market volatility and tariff fears to build high-conviction positions in undervalued CROs and technology leaders.
Full Quick Take
The Oakmark Select Fund underperformed the S&P 500 in Q2 2025 but leveraged market volatility and tariff fears to build high-conviction positions in undervalued CROs and technology leaders.
Vulcan Value Partners capitalized on Q2 2025's tariff-induced market volatility to actively reallocate capital, buying deeply discounted stable-value giants like UnitedHealth and IQVIA while trimming fully valued holdings.
Full Quick Take
Vulcan Value Partners capitalized on Q2 2025's tariff-induced market volatility to actively reallocate capital, buying deeply discounted stable-value giants like UnitedHealth and IQVIA while trimming fully valued holdings.
Vulcan Value Partners capitalized on Q2 2025 tariff-related volatility, actively reallocating capital to pick up discounted healthcare and industrial compounders, notably repurchasing UnitedHealth Group after a severe pullback.
Full Quick Take
Vulcan Value Partners capitalized on Q2 2025 tariff-related volatility, actively reallocating capital to pick up discounted healthcare and industrial compounders, notably repurchasing UnitedHealth Group after a severe pullback.
Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare and technology leaders.
Full Quick Take
Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare and technology leaders.
